SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020)
Clin. transl. oncol. (Print)
; 23(5): 980-987, mayo 2021. tab
Article
in English
| IBECS
| ID: ibc-221238
Responsible library:
ES1.1
Localization: ES15.1 - BNCS
ABSTRACT
Mesothelioma is a rare and aggressive tumour with dismal prognosis arising in the pleura and associated with asbestos exposure. Its incidence is on the rise worldwide. In selected patients with early-stage MPM, a maximal surgical cytoreduction in combination with additional antitumour treatment may be considered in selected patients assessed by a multidisciplinary tumor board. In patients with unresectable or advanced MPM, chemotherapy with platinum plus pemetrexed is the standard of care. Currently, no standard salvage therapy has been approved yet, but second-line chemotherapy with vinorelbine or gemcitabine is commonly used. Novel therapeutic approaches based on dual immunotherapy or chemotherapy plus immunotherapy demonstrated promising survival benefit and will probably be incorporated in the future (AU)
Full text:
Available
Collection:
National databases
/
Spain
Database:
IBECS
Main subject:
Pleural Neoplasms
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Clin. transl. oncol. (Print)
Year:
2021
Document type:
Article
Institution/Affiliation country:
Complejo Hospitalario Universitario A Coruña/Spain
/
Complejo Hospitalario de Jaén/Spain
/
Hospital Clínico Universitario de Valladolid/Spain
/
Hospital General Universitario de Elche/Spain
/
Hospital Josep Trueta/Spain
/
Hospital Son Llatzer/Spain
/
Hospital Universitari Vall dHebron/Spain
/
Hospital Universitario La Paz/Spain
/
Hospital Universitario Virgen de Macarena/Spain
/
lHospitalet de Llobregat/Spain